Charles River Labs upgraded to Buy from Hold at Jefferies Jefferies upgraded Charles River Labs citing valuation and a rebound in R&D spending. The firm raised its price target for shares to $50 from $41.
News For CRL From The Last 14 Days
Check below for free stories on CRL the last two weeks.
Charles River Labs has reached attractive entry point, says Sterne Agee Sterne Agee continues to believe that Charles River should generate high incremental margins and disproportionate growth in earnings relative to its sales growth. The firm keeps a $71 price target and Buy rating on the shares.